{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:25Z","timestamp":1788498925307,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After microsurgical clipping for aneurysmal subarachnoid hemorrhage (aSAH), sedation should preserve neurological examinability without compromising hemodynamics or nimodipine delivery. We examined whether early postoperative dexmedetomidine was associated with a greater post-landmark RASS-defined examinability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed adults with aSAH treated with clipping at one center from October 2021 to October 2025. Early dexmedetomidine was initiation within 24\u202fh after clipping and continuation for at least 2\u202fh. Exposure was classified during 0\u201324\u202fh. The primary endpoint was the time-weighted proportion of observed 24\u201372\u202fh time in RASS-defined examinability defined without reference to the contemporaneous ordered target (Richmond Agitation-Sedation Scale [RASS] \u22122 to 0). Ordered-target attainment was the key secondary endpoint. Hour-level states were modeled in consecutive 6-h bins using generalized estimating equations (GEE); target-conditional and shared examinable-target-band analyses tested whether easier prescription targets explained the association. The endpoint hierarchy was finalized after data analysis during peer review; the study was not preregistered, no multiplicity adjustment was applied, and all estimates are exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 123 eligible patients, 120 were alive and classifiable at 24\u202fh; 41 received early dexmedetomidine and 79 did not. Examinable time during 24\u201372\u202fh was 68% versus 55% (Hodges-Lehmann location shift, 12 percentage points; 95% CI, 5\u201319), and the GEE-adjusted marginal difference was 11.8 points (95% CI, 4.1\u201319.5). Early users had less post-landmark deep-sedation time; post-landmark co-sedative exposure, dose, and duration differences were directionally lower but imprecise. Ordered-target attainment was directionally concordant; the primary association remained after adding ordered-target stratum and in the shared-target restriction. Window-specific differences were 15.2 points (95% CI, 6.0\u201324.4) and 6.3 points (95% CI, \u22122.4 to 15.0); the exposure-by-window interaction was imprecise (difference-in-differences, 8.9 points; 95% CI, \u22123.6 to 21.4;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.164). Bradycardia was more frequent (22.0% vs. 7.6%; risk difference, 14.4 points; 95% CI, 1.6\u201329.7), whereas other safety estimates were imprecise.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The principal finding was greater post-landmark RASS-defined examinability; related care-process and co-sedative measures were not independent validation. Its descriptive concentration during 24\u201348\u202fh was not confirmed by the formal interaction test and remains hypothesis-generating, with bradycardia as the principal trade-off. The findings remain vulnerable to confounding by indication and do not establish a drug-specific causal effect or downstream clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1908727","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:40Z","timestamp":1788495880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early dexmedetomidine and postoperative RASS-defined examinability after microsurgical clipping for aneurysmal subarachnoid hemorrhage: a time-resolved 24-h landmark cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Guilan","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Dazhou First People's Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlai","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangde","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Dazhou Central Hospital","place":["Dazhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","article-title":"2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"54","author":"Hoh","year":"2023","journal-title":"Stroke"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-023-01713-5","article-title":"Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage","volume":"39","author":"Treggiari","year":"2023","journal-title":"Neurocrit Care"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00134-024-07387-7","article-title":"Contemporary management of aneurysmal subarachnoid haemorrhage: an update for the intensivist","volume":"50","author":"Robba","year":"2024","journal-title":"Intensive Care Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/ALN.0000000000003558","article-title":"Perioperative management of aneurysmal subarachnoid hemorrhage","volume":"133","author":"Sharma","year":"2020","journal-title":"Anesthesiology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","article-title":"Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU","volume":"46","author":"Devlin","year":"2018","journal-title":"Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12028-024-02111-1","article-title":"The impact of sedative choice in the management of aneurysmal subarachnoid hemorrhage: a scoping review","volume":"42","author":"Then","year":"2025","journal-title":"Neurocrit Care"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1058804","DOI":"10.3389\/fneur.2023.1058804","article-title":"Sedation protocols in non-traumatic SAH (SPRINT-SAH): a cross-sectional survey among German-speaking neurointensivists","volume":"14","author":"Schmidbauer","year":"2023","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1363107","DOI":"10.3389\/fneur.2024.1363107","article-title":"Risk factors and outcomes after interruption of sedation in subarachnoid hemorrhage (ROUTINE-SAH): a retrospective cohort study","volume":"15","author":"Schmidbauer","year":"2024","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/ANA.0000000000000728","article-title":"Role of dexmedetomidine in aneurysmal subarachnoid hemorrhage: a comprehensive scoping review","volume":"34","author":"Liu","year":"2022","journal-title":"J Neurosurg Anesthesiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fphar.2019.00858","article-title":"The nimodipine-sparing effect of perioperative dexmedetomidine infusion during aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial","volume":"10","author":"Ren","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/aas.13663","article-title":"Cerebral autoregulation after aneurysmal subarachnoid haemorrhage: a preliminary study comparing dexmedetomidine to propofol and\/or midazolam","volume":"64","author":"Kallioinen","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"110106","DOI":"10.1016\/j.jclinane.2020.110106","article-title":"A retrospective observational pilot study on the effects of dexmedetomidine on neurological outcomes after aneurysmal subarachnoid hemorrhage","volume":"68","author":"Esfahani","year":"2021","journal-title":"J Clin Anesth"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcrc.2017.10.034","article-title":"Association between dexmedetomidine use and neurological outcomes in aneurysmal subarachnoid hemorrhage patients: a retrospective observational study","volume":"44","author":"Okazaki","year":"2018","journal-title":"J Crit Care"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"29590","DOI":"10.1038\/s41598-024-81025-6","article-title":"A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1554809","DOI":"10.3389\/fneur.2025.1554809","article-title":"Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses","volume":"16","author":"Li","year":"2025","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"123539","DOI":"10.1016\/j.wneu.2024.11.122","article-title":"Dexmedetomidine is associated with reduced in-hospital mortality risk of patients with subarachnoid hemorrhage undergoing surgery","volume":"194","author":"Liu","year":"2025","journal-title":"World Neurosurg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/ANA.0000000000001069","article-title":"Comparison of the effect of low-dose and standard-dose dexmedetomidine infusion on neurological outcomes in patients with aneurysmal subarachnoid hemorrhage undergoing aneurysmal neck clipping: a randomized controlled trial","volume":"38","author":"Pal","year":"2025","journal-title":"J Neurosurg Anesthesiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","article-title":"Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group","volume":"41","author":"Vergouwen","year":"2010","journal-title":"Stroke"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","article-title":"Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial","volume":"298","author":"Pickard","year":"1989","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12028-024-02182-0","article-title":"Nimodipine in aneurysmal subarachnoid hemorrhage: are old data enough to justify its current treatment regimen?","volume":"42","author":"Llompart-Pou","year":"2025","journal-title":"Neurocrit Care"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"j5745","DOI":"10.1136\/bmj.j5745","article-title":"Development and validation of outcome prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT multinational cohort study","volume":"360","author":"Jaja","year":"2018","journal-title":"BMJ"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1908727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:40Z","timestamp":1788495880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1908727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":25,"alternative-id":["10.3389\/fneur.2026.1908727"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1908727","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1908727"}}